Herborium Group upgrades its forecasts for 2013 with AcnEase® sales showing
continuous high growth
Herborium's one of a kind Botanical Therapeutic® for Acne expected to double
its sale in 2013; the worldwide investor awareness campaign to begin
FORT LEE, N.J., Jan. 29, 2013
FORT LEE, N.J., Jan. 29, 2013 /PRNewswire/ -- Herborium Group, Inc., (OTC
Pink: HBRM) www.herborium.com, a Botanical Therapeutics® Company is happy to
upgrade its expected revenues projections for 2013 discussed in the Press
Release of October 15, 2012.
End of 2012 sales results for AcnEase®, Herborium's one of a kind Botanical
Therapeutic® for acne, and AcnEase® performance in the two first months of
the First Quarter of 2013, show a consistent growth of over 20% per
quarter, therefore allowing to expect direct sales revenues from the product
to more than double in the present year. This growth should consequently
increase the expected total revenues of the Company to exceed seven figures.
Worldwide investor awareness campaign to increase investor value resulted from
this progress is to start immediately.
AcnEase® www.acnease.com, targets over 60 million acne sufferers in the US
with a specific focus on Adult Acne (average age of acne sufferer in the USA
increased from 21.5 to 26.5 during a last decade). After a withdrawal of
Accutane (Roche Pharmaceuticals) from the market due to safety concerns, this
dramatically growing and health conscious market was left without an effective
treatment. AcnEase® is an all natural and effective treatment for adult acne,
and is gaining the enthusiastic reviews from its users. In addition to the US
market, AcnEase® is gaining momentum in Canada, has became a treatment of
choice for male acne in UK, and is steadily increasing its brand recognition
in other EU countries. Over 70 million people in Europe suffers from acne.
Herborium has also recently received a qualified interest for distribution of
AcnEase® in South-East Asia.
"We are very pleased with the AcnEase® sales results of in 2012, and with its
momentum in 2013. We expect this sales progress to continue aggressively. In
addition to a domestic growth, an opportunity to enter new markets and new
distribution arrangements abroad should become a lynchpin of Herborium's
profitability in 2013," commented Dr. Agnes P. Olszewski, CEO and Chairwomen
of Herborium Group.
About Herborium Group, Inc.
Herborium Group, Inc., a Botanical Therapeutics® company, focuses on
developing, licensing, and marketing proprietary, botanical based medicinal
products to consumers and healthcare professionals. The Company uses clinical
validation to establish and maintain a differential advantage. The company
sells its products in the US and Europe. For more information, please visit
www.herborium.com and www.acnease.com
One of our most important responsibilities is to communicate with shareholders
in an open and direct manner. Comments are based on current management
expectations, and are considered "forward-looking statements," generally
preceded by words such as "plans," "expects," "believes," "anticipates," or
"intends." We cannot promise future returns. Our statements reflect our best
judgment at the time, and we disclaim any obligation to update or alter
forward-looking statements as the result of new information or future events.
The Company urges investors to review the risks and uncertainties contained
within its filings with the OTC Markets and/or Securities and Exchange
For more information please inquire: Investorsrelations@herborium.com
SOURCE Herborium Group, Inc.
Press spacebar to pause and continue. Press esc to stop.